<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791778</url>
  </required_header>
  <id_info>
    <org_study_id>12007</org_study_id>
    <secondary_id>2008-004429-41</secondary_id>
    <nct_id>NCT00791778</nct_id>
  </id_info>
  <brief_title>Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer</brief_title>
  <official_title>A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced
      Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen
      of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment</measure>
    <time_frame>From randomization of the first patient until 32.5 months later, assessed every 8 weeks</time_frame>
    <description>Time from randomization to the first documented disease progression by radiological or pathologic assessment or death due to any cause whichever occurred first. For patients who had not progressed or died at the time of analysis, PFS was censored at the date of their last evaluable tumor scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Pathologic CA-125 (Cancer-associated Tumor Marker) Serum Level</measure>
    <time_frame>From randomization of the first patient until 32.5 months later, assessed every 8 weeks</time_frame>
    <description>Time from randomization to the first documented increase of CA-125 above the upper limit of normal. Patients without pathologic CA-125 increase at the time of analysis were censored at their last date of evaluation of CA-125.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization of the first patient until 32.5 months later</time_frame>
    <description>The OS time was measured from the date of randomization until the date of death due to any cause. Patients who were alive at the time of analysis were censored at the date of the last contact (last time the patient was known to be alive).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Assessment of Cancer Therapy (FACT)/National Comprehensive Cancer Network (NCCN) Ovarian Symptom Index (FOSI) Total Score at Cycle 1/Baseline</measure>
    <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
  </other_outcome>
  <other_outcome>
    <measure>FOSI Total Score at Cycle 3</measure>
    <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in FOSI Total Score at Cycle 3</measure>
    <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 3 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>FOSI Total Score at Cycle 5</measure>
    <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in FOSI Total Score at Cycle 5</measure>
    <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 5 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>FOSI Total Score at End of Treatment</measure>
    <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in FOSI Total Score at End of Treatment</measure>
    <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at End of treatment minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EuroQol-5D (EQ-5D) Index Score at Cycle 1/Baseline</measure>
    <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D Index Score at Cycle 3</measure>
    <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D Index Score at Cycle 3</measure>
    <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D Index Score at Cycle 5</measure>
    <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D Index Score at Cycle 5</measure>
    <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D Index Score at End of Treatment</measure>
    <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D Index Score at End of Treatment</measure>
    <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D Visual Analogue Scale (VAS) Score at Cycle 1/Baseline</measure>
    <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D VAS Score at Cycle 3</measure>
    <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D VAS Score at Cycle 3</measure>
    <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D VAS Score at Cycle 5</measure>
    <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D VAS Score at Cycle 5</measure>
    <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D VAS Score at End of Treatment</measure>
    <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in EQ-5D VAS Score at End of Treatment</measure>
    <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
    <description>The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 2 matching placebo tablets per oral twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO)
             stage (67) III or IV ovarian epithelial cancer or primary peritoneal cancer at
             presentation. Patients must have achieved a clinical complete response (disappearance
             of all clinical and radiological evidence of tumor) after only one regimen (4-6
             cycles) of platinum and taxane-based standard chemotherapy received after tumor
             debulkment.

          -  Normal serum CA125 (cancer-associated tumor marker) level within 7 days of first dose
             of sorafenib.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  All scans used to document complete response must be done within 30 days prior to
             randomization.

          -  Patients must be able to swallow and retain oral medication.

        Exclusion Criteria:

          -  Patients with any residual cancer tissue after the completion of chemotherapy
             detectable by standard Computed tomography (CT) or magnetic resonance imaging (MRI).

          -  Prior local radiotherapy, neoadjuvant chemotherapy or intraperitoneal chemotherapy.

          -  Histologic subtypes of ovarian cancer other than epithelial (i.e. sarcoma, lymphoma,
             germ cell).

          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <zip>FI-40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <zip>FIN- 70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ANGERS cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>39373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>HongKong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meldola</city>
        <state>Forlì</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campobasso</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sowon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Herzog TJ, Scambia G, Kim BG, Lhommé C, Markowska J, Ray-Coquard I, Sehouli J, Colombo N, Shan M, Petrenciuc O, Oza A. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013 Jul;130(1):25-30. doi: 10.1016/j.ygyno.2013.04.011. Epub 2013 Apr 13.</citation>
    <PMID>23591401</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <results_first_submitted>November 1, 2012</results_first_submitted>
  <results_first_submitted_qc>November 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2012</results_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal Neoplasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received 2 matching placebo tablets per oral twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46">includes: 42 subjects with progression, 4 subjects transferred to a continuation study</participants>
                <participants group_id="P2" count="75">includes: 75 subjects with progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with study medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95">Includes 79 participants with study follow-up terminated by sponsor and 16 deaths</participants>
                <participants group_id="P2" count="90">Includes 78 participants with study follow-up terminated by sponsor and 12 deaths</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received 2 matching placebo tablets per oral twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="10.4"/>
                    <measurement group_id="B2" value="54.4" spread="10.3"/>
                    <measurement group_id="B3" value="55.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 - &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance status, Eastern Cooperative Oncology Group (ECOG)</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects the daily life of a patient on an ordinal scale from grade 0 (best) to grade 5 (worst).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0=Fully active without restriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=Restricted in physically strenuous activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=Ambulatory, capable of all selfcare</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of cancer</title>
          <description>Patients were to have either ovarian epithelial cancer or primary peritoneal cancer. Primary peritoneal carcinoma involves the extra-ovarian peritoneum significantly and the ovarian surface minimally or not at all.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ovarian cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Intra-peritoneal (IP) chemotherapy</title>
          <description>The presence or absence of any IP chemotherapy before enrollment into the study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical cytoreduction</title>
          <description>The degree of residual disease following initial diagnosis and surgical debulkment: optimal surgical cytoreduction (any/each lesion remaining after surgery ≤1 cm) or suboptimal surgical cytoreduction (any/each lesion remaining after surgery &gt;1cm)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suboptimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment</title>
        <description>Time from randomization to the first documented disease progression by radiological or pathologic assessment or death due to any cause whichever occurred first. For patients who had not progressed or died at the time of analysis, PFS was censored at the date of their last evaluable tumor scan.</description>
        <time_frame>From randomization of the first patient until 32.5 months later, assessed every 8 weeks</time_frame>
        <population>Full analysis set (FAS)=all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment</title>
          <description>Time from randomization to the first documented disease progression by radiological or pathologic assessment or death due to any cause whichever occurred first. For patients who had not progressed or died at the time of analysis, PFS was censored at the date of their last evaluable tumor scan.</description>
          <population>Full analysis set (FAS)=all randomized participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386" lower_limit="230" upper_limit="691"/>
                    <measurement group_id="O2" value="478" lower_limit="337" upper_limit="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on the primary efficacy endpoint of PFS. Clinically meaningful improvement defined as 65% increase in median PFS. With one-sided alpha of 0.10, power of 90% and a randomization ratio of 1:1 between Sorafenib and Placebo, a total of 105 PFS events were required.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <method>Log Rank</method>
            <method_desc>Two treatment groups compared using a log-rank test with one-sided alpha of 0.10 stratified by the same factors as randomization</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>Sorafenib compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Pathologic CA-125 (Cancer-associated Tumor Marker) Serum Level</title>
        <description>Time from randomization to the first documented increase of CA-125 above the upper limit of normal. Patients without pathologic CA-125 increase at the time of analysis were censored at their last date of evaluation of CA-125.</description>
        <time_frame>From randomization of the first patient until 32.5 months later, assessed every 8 weeks</time_frame>
        <population>Per protocol set (PPS)=all randomized participants who had normal CA-125 serum level at baseline and at least one post-baseline CA-125 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Pathologic CA-125 (Cancer-associated Tumor Marker) Serum Level</title>
          <description>Time from randomization to the first documented increase of CA-125 above the upper limit of normal. Patients without pathologic CA-125 increase at the time of analysis were censored at their last date of evaluation of CA-125.</description>
          <population>Per protocol set (PPS)=all randomized participants who had normal CA-125 serum level at baseline and at least one post-baseline CA-125 assessment</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337" lower_limit="197">Can't be estimated due to censored data.</measurement>
                    <measurement group_id="O2" value="617" lower_limit="392">Can't be estimated due to censored data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>Log Rank</method>
            <method_desc>Two treatment groups compared using a log-rank test with one-sided alpha of 0.10 stratified by the same factors as randomization</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
            <estimate_desc>Sorafenib compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>The OS time was measured from the date of randomization until the date of death due to any cause. Patients who were alive at the time of analysis were censored at the date of the last contact (last time the patient was known to be alive).</description>
        <time_frame>From randomization of the first patient until 32.5 months later</time_frame>
        <population>FAS=all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The OS time was measured from the date of randomization until the date of death due to any cause. Patients who were alive at the time of analysis were censored at the date of the last contact (last time the patient was known to be alive).</description>
          <population>FAS=all randomized participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Can't be estimated due to censored data.</measurement>
                    <measurement group_id="O2" value="NA">Can't be estimated due to censored data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Log Rank</method>
            <method_desc>Two treatment groups compared using a log-rank test with one-sided alpha of 0.10 stratified by the same factors as randomization.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
            <estimate_desc>Sorafenib compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Assessment of Cancer Therapy (FACT)/National Comprehensive Cancer Network (NCCN) Ovarian Symptom Index (FOSI) Total Score at Cycle 1/Baseline</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
        <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
        <population>Patient-reported outcomes (PRO) analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy (FACT)/National Comprehensive Cancer Network (NCCN) Ovarian Symptom Index (FOSI) Total Score at Cycle 1/Baseline</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
          <population>Patient-reported outcomes (PRO) analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.909" spread="3.174"/>
                    <measurement group_id="O2" value="25.658" spread="3.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>FOSI Total Score at Cycle 3</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
        <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>FOSI Total Score at Cycle 3</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.871" spread="3.166"/>
                    <measurement group_id="O2" value="26.105" spread="3.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in FOSI Total Score at Cycle 3</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 3 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FOSI Total Score at Cycle 3</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 3 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="3.387"/>
                    <measurement group_id="O2" value="0.460" spread="3.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>FOSI Total Score at Cycle 5</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
        <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>FOSI Total Score at Cycle 5</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.496" spread="3.830"/>
                    <measurement group_id="O2" value="26.634" spread="2.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in FOSI Total Score at Cycle 5</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 5 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FOSI Total Score at Cycle 5</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 5 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.223" spread="3.530"/>
                    <measurement group_id="O2" value="0.659" spread="3.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>FOSI Total Score at End of Treatment</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
        <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>FOSI Total Score at End of Treatment</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.011" spread="3.832"/>
                    <measurement group_id="O2" value="24.528" spread="3.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in FOSI Total Score at End of Treatment</title>
        <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at End of treatment minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
        <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FOSI Total Score at End of Treatment</title>
          <description>The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at End of treatment minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.733" spread="4.089"/>
                    <measurement group_id="O2" value="-1.088" spread="4.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EuroQol-5D (EQ-5D) Index Score at Cycle 1/Baseline</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
        <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol-5D (EQ-5D) Index Score at Cycle 1/Baseline</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.804" spread="0.168"/>
                    <measurement group_id="O2" value="0.779" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D Index Score at Cycle 3</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
        <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Index Score at Cycle 3</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.727" spread="0.219"/>
                    <measurement group_id="O2" value="0.767" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D Index Score at Cycle 3</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Index Score at Cycle 3</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" spread="0.225"/>
                    <measurement group_id="O2" value="-0.003" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D Index Score at Cycle 5</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
        <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Index Score at Cycle 5</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.744" spread="0.217"/>
                    <measurement group_id="O2" value="0.813" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D Index Score at Cycle 5</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Index Score at Cycle 5</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" spread="0.222"/>
                    <measurement group_id="O2" value="0.016" spread="0.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D Index Score at End of Treatment</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
        <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Index Score at End of Treatment</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied.</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.731" spread="0.235"/>
                    <measurement group_id="O2" value="0.741" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D Index Score at End of Treatment</title>
        <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
        <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Index Score at End of Treatment</title>
          <description>The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" spread="0.243"/>
                    <measurement group_id="O2" value="-0.054" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D Visual Analogue Scale (VAS) Score at Cycle 1/Baseline</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>At Cycle 1 (4 weeks per Cycle)/baseline</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Visual Analogue Scale (VAS) Score at Cycle 1/Baseline</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at least one post-baseline assessment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.235" spread="14.494"/>
                    <measurement group_id="O2" value="75.868" spread="16.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D VAS Score at Cycle 3</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>At Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D VAS Score at Cycle 3</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.042" spread="14.701"/>
                    <measurement group_id="O2" value="77.899" spread="16.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D VAS Score at Cycle 3</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 3 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D VAS Score at Cycle 3</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.225" spread="15.594"/>
                    <measurement group_id="O2" value="2.688" spread="10.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D VAS Score at Cycle 5</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>At Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D VAS Score at Cycle 5</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.404" spread="14.177"/>
                    <measurement group_id="O2" value="79.915" spread="16.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D VAS Score at Cycle 5</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
        <time_frame>Baseline and Cycle 5 (4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D VAS Score at Cycle 5</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at Cycle 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.947" spread="15.901"/>
                    <measurement group_id="O2" value="3.543" spread="14.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EQ-5D VAS Score at End of Treatment</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>At End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D VAS Score at End of Treatment</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.413" spread="16.686"/>
                    <measurement group_id="O2" value="76.246" spread="16.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in EQ-5D VAS Score at End of Treatment</title>
        <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
        <time_frame>Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)</time_frame>
        <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 matching placebo tablets per oral twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D VAS Score at End of Treatment</title>
          <description>The EQ-5D also contains a VAS, which records the respondent’s self-rated health status on a vertical graduated scale. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline).</description>
          <population>PRO analysis set=the FAS population with evaluable PRO assessments at baseline and at end of treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.147" spread="18.054"/>
                    <measurement group_id="O2" value="0.348" spread="17.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment up to 30 days after last study drug administration.</time_frame>
      <desc>Acronyms used: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE)</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received 2 matching placebo tablets per oral twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE (v.3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SupraVentricular arrhythmia, Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Colon/Cecum/Appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Ileum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>No Code In CTCAE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Allergy - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (Documented clinically), Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraop injury - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy (possibly related to cancer treatment)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration, Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula, GU, Vagina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE (v.3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Extremity - limb</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain, Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (Documented clinically), Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

